. The company’s pipeline incorporates 4 scientific-stage therapies. Its most Sophisticated drug candidate is ROS1 inhibitor taletrectinib for treating lung most cancers. Nuvation is completing two stage 2 pivotal experiments on taletrectinib. The high-risk mother nature of these stocks means they will experience significant price swings, normally pushed by https://financefeeds.com/transficc-raises-25-million-in-series-b-round-led-by-citadel-securities/